Grand jury probes Vioxx marketing

A federal grand jury is investigating Merck's marketing of Vioxx, the infamous painkiller pulled from the market in 2004. The Wall Street Journal reports that a health-care fraud unit in the U.S. Attorney's Office for the District of Massachusetts is probing whether Merck promoted the drug for off-label use.

According to a filing with the SEC, Merck was subpoenaed by the Justice Department for information about research, marketing and sales of Vioxx. Thirty-one attorneys general and the District of Columbia are looking into Vioxx marketing, the company disclosed.

Previous Justice Department probes into drug marketing have cost pharma millions; AstraZeneca paid $355 million in 2003, for instance. And it comes as Merck is hoping to wrap up litigation over the withdrawn drug with a $4.85 billion settlement. One attorney involved in the Vioxx litigation told the WSJ that the potential of a grand-jury indictment could have been an incentive for Merck to settle its civil claims.

Speaking of marketing-related lawsuits, two Springfield, Illinois, doctors have sued a Merck rep, alleging that she sent anonymous letters claiming the docs and their wives are obnoxious, greedy, and heavy drinkers. The letters surfaced after a Merck-hosted dinner, where one of the docs asked about the cardiovascular side effects of Merck's Zostavax vaccine. Merck declined comment on the suit.

- read the article from the Wall Street Journal
- check out coverage of the doctors' lawsuit in The Springfield Journal-Register
- see Pharmalot's item

Related Articles:
Rep decries off-label marketing "loophole." Report
Vioxx settlement spawns mega-chatter. Report
Merck settling Vioxx claims for $4.85B. Report

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.